Luca Grisetti

Dr. Luca Grisetti

Fondazione Italiana Fegato, Trieste, Friuli-Venezia Giulia, Italy
+2
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Loraine CabralLoraine Cabral
Loraine Cabral
Luca GrisettiLuca Grisetti
Luca Grisetti
MPMuhammad Yogi Pratama
Muhammad Yogi Pratama
CTClaudio Tiribelli
Claudio Tiribelli
DPDevis Pascut
Devis Pascut
Hepatocellular carcinoma (HCC) is the sixth-most common type of cancer worldwide and chronic Hepatitis C virus (HCV) represents the main etiological factor in developed countries. HCV promotes hepatocarcinogenesis through persistent liver inflammation and dysregulation of cell signaling pathways. The introduction of direct-acting antivirals (DAAs) resulted in a significant improvement in the eradication of the virus, with an expected reduction of HCC incidence. However, the risk of HCC development can persist after DAA treatment. Recent studies have investigated the potential use of molecular biomarkers that predict HCC occurrence or recurrence helping the stratification of patients under surveillance. This review aimed to summarize all pre-clinical exploration of predictive biomarkers to identify DAA-treated patients at risk for HCC development. Dysregulated microRNAs, lncRNAs, histone modifications, cytokines, proteins, and sphingolipids represent various classes of HCC risk predictors identified in two different biological sources (tissue and serum). The non-invasive serum markers can provide a more accessible means to perform clinical monitoring and predict the risk of HCC. In addition, conditions like cirrhosis, predisposing to HCC, strongly correlate with most of the molecular predictors identified, supporting the value of these molecules as possible biomarkers of HCC in DAA-treated patients.

19 December 2022 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
Luca GrisettiLuca Grisetti
Luca Grisetti
NVNiệm Văn Thành Võ
Niệm Văn Thành Võ
NNNhư Nhật Quỳnh Nguyễn
Như Nhật Quỳnh Nguyễn
LCLory Saveria Crocè
Lory Saveria Crocè
AVAlessia Visintin
Alessia Visintin
DPDevis Pascut
Devis Pascut
Background: Hepatic resection, radiofrequency ablation (RF), and liver transplantation (LT) represent the only available curative treatments for early stage hepatocellular carcinoma (HCC). Various studies showed that the 5-year overall survival (OS) rate reaches ∼70% after resection and ∼60% after RF. Objective: To improve the success rate of curative therapies and consequently the OS, an improvement in patients’ selection and management should be pursued. In this regard, microRNAs (miRNAs) can be helpful prognostic biomarkers. Materials and Methods: In this retrospective study, a miRNA array profiling was performed on 34 HCC blood samples which is collected before therapy (T0), 1 month (T1), and 6 months (T2) after curative treatments (resection and RF) to identify noninvasive biomarker candidates for therapy response and OS. MiRNAs were validated in 80 blood HCC samples using quantitative real-time PCR (qRT-PCR). Patients were divided into complete responder (CR) and partial responder and progressive disease (PRPD). Results: Among the selected miRNAs, miR-3201 is significantly associated with treatment response in the validation phase, showing a 23% reduction ( P = .026) in CR compared to PRPD. MiR-3201 was able to distinguish CR from PRPD (area under the curve [AUC] = 0.69, 71% sensitivity, 70% specificity, P = .0036). Furthermore, lower levels of miR-3201 were associated with longer OS (hazard ratio [HR] = 2.61, P = .0006). Conclusions: Blood miR-3201 could be used as a prognostic biomarker for curative therapy response and OS in HCC.

6 November 2024 in Life
Verified
Journal Article
Open access
PDF file
CGClarissa Joy C. Garcia
Clarissa Joy C. Garcia
Luca GrisettiLuca Grisetti
Luca Grisetti
CTClaudio Tiribelli
Claudio Tiribelli
DPDevis Pascut
Devis Pascut
Hepatocellular carcinoma (HCC) represents a major public health concern and ranks among the leading cancer-related mortalities globally. Due to the frequent late-stage diagnosis of HCC, therapeutic options remain limited. Emerging evidence highlights the critical role of non-coding RNAs (ncRNAs) in the regulation of Aurora kinase A (AURKA), one of the key hub genes involved in several key cancer pathways. Indeed, the dysregulated interaction between ncRNAs and AURKA contributes to tumor development, progression, and therapeutic resistance. This review delves into the interplay between ncRNAs and AURKA and their role in hepatocarcinogenesis. Recent findings underscore the involvement of the ncRNAs and AURKA axis in tumor development and progression. Furthermore, this review also discusses the clinical significance of targeting ncRNA-AURKA axes, offering new perspectives that could lead to innovative therapeutic strategies aimed at improving outcomes for HCC patients.

1 May 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
Luca GrisettiLuca Grisetti
Luca Grisetti
CGClarissa J. C. Garcia
Clarissa J. C. Garcia
PTPaola Tarchi
Paola Tarchi
CTClaudio Tiribelli
Claudio Tiribelli
DPDevis Pascut
Devis Pascut
Introduction: Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis have expanded treatment options for hepatocellular carcinoma (HCC), yet only a subset of patients achieves durable responses. Limited efficacy reflects gaps in understanding PD-L1 regulation, including its biochemical heterogeneity, subtype-specific stability, and effects on tumor–immune interactions. We aimed to dissect these mechanisms and identify integrated biomarkers predictive of immunotherapy response. Methods: Human HCC and paired non-tumoral tissues, an HBV-driven transgenic mouse model, and five HCC cell lines representing Hoshida/Caruso subtypes were analyzed. PD-L1 expression, glycosylation, and stability were assessed by Western blot, flow cytometry, and immunohistochemistry. Functional assays included co-cultures of HCC cells with primary activated PBMCs from multiple healthy donors. Cells were treated with durvalumab or atezolizumab, in the presence or absence of IFN-γ stimulation. PD-L1 turnover was evaluated using cycloheximide and proteasome inhibition. Results: PD-L1 protein was increased in ~60% of tumors, particularly in virally driven HCC. Elevated PD-L1 in non-tumoral liver was associated with higher recurrence risk. Biochemical profiling revealed multiple PD-L1 species: mature N-glycosylated and intermediate forms indicative of enhanced stability were enriched in tumors. Glycosylated PD-L1 displayed prolonged half-life in S1/CL3 subtypes, whereas S2/CL1 cells exhibited rapid, proteasome-dependent turnover. PD-L1 abundance alone did not predict immune susceptibility: S1-like cells, despite higher PD-L1, were highly sensitive to CD8 + T-cell–mediated killing and PD-L1 blockade, whereas S2-like cells were more resistant to cytotoxicity. ICIs induced donor-dependent cytotoxicity, with variable responder profiles; durvalumab outperformed atezolizumab, consistent with reduced glycosylation dependence. IFN-γ priming enhanced PD-L1 expression and restored immune responsiveness in low-responder co-cultures. Overall, tumors with stable glycosylated PD-L1 (S1-like) rely on PD-L1–mediated immune suppression and may benefit from PD-L1–targeted therapies, whereas tumors with low or rapidly turned-over PD-L1 (S2-like) exhibit dynamic PD-L1 regulation with increased reliance on de novo synthesis, limiting responsiveness to PD-L1 blockade alone and supporting the need for combinatorial approaches. Conclusions: PD-L1 regulation in HCC depends on molecular subtype, post-translational stability, and host immune competence. Integrating these factors provides a framework for guiding patient selection and optimizing immunotherapy.